131805-94-2

Basic information

• Product Name: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE
• Synonyms: BUTTPARK 41\03-56;3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE;3,5-BIS(TRIFLUOROMETHYL)PHENACYL BROMIDE;2-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANONE;2-BROMO-1-[3,5-DI(TRIFLUOROMETHYL)PHENYL]ETHAN-1-ONE;2-Bromo-1-[3,5-di(trifluoromethyl)phenyl]ethan-1-one, 95+%;3,5-Bis(trifluoromethyl)phenacyl bromide 97%;3,5-Bis(trifluoromethyl)phenacylbromide97%
• CAS NO: 131805-94-2
• Molecular Formula: C₁₀H₅BrF₆O
• Molecular Weight: 335.04
• Product Categories: Benzene series
• Mol File: 131805-94-2.mol
• Article Data: 11

Chemical Properties

• Melting Point: 44-46
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(131805-94-2)
• EPA Substance Registry System: 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE(131805-94-2)

Safety Data

• Hazard Codes: Xi
• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 1760
• HazardClass: IRRITANT
• Hazardous Substances Data: 131805-94-2(Hazardous Substances Data)

Usage

General Description

3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is a chemical compound with the molecular formula C10H5BrF6O. It is a white to light yellow crystalline solid that is insoluble in water but soluble in organic solvents. 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a building block in the production of fluorinated organic compounds. Additionally, 3',5'-BIS(TRIFLUOROMETHYL)-2-BROMOACETOPHENONE is known for its strong electron-withdrawing properties, making it valuable in organic synthesis. However, it is important to handle this compound with care as it may be harmful if swallowed, inhaled, or in contact with the skin and eyes.

Upstream product

• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 1246224-45-2 1-(bromoethynyl)-3,5-bis(trifluoromethyl)benzene 
• 186581-53-3 diazomethane 
• 725-89-3 3,5-bistrifluoromethylbenzoic acid 

Downstream Products

• 284665-41-4 2-[3',5'-bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyridine 
• 254910-94-6 methyl 4-[4-[3,5-bis(trifluoromethyl)phenyl]-2-oxazolyl]benzoate 
• 237384-88-2 methyl 4-{4-[3,5-bis(trifluoromethyl)phenyl](1,3-thiazol-2-yl)}-5-methylthiothiophene-2-carboxylate 

Relevant articles and documents

Synthesis and structural elucidation of novel 2,4-Disubstituted 1,3-Oxazole analogues for pharmacological properties

A series of novel 2,4-disubstituted 1,3-oxazole analogues (3a-i) has been designed and synthesized between 1-[3,5-bis(trifluoromethyl)-phenyl]-2-bromoethan-1-one and substituted amides by microwave assisted method. 2,4-Disubstituted 1,3-oxazole analogues

An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases

Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different disease pathologies. Although a number of computational protocols have been published for identifying druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique opportunity for the efficient integration of warhead-optimization and target-validation into the covalent drug development process. Screening this probe kit against multiple kinases could experimentally characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retrospectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor programs.

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formu